Hemophilia A treatment market sales were 66 billion won

ADVATE· Novoseven sluggish, Adynovate·Hemlibra on the rise

Hemlibra, sales of 7.6 billion won last year, successful evaluation of soft landing in the market in the 3rd year of release

Hemlibra

Last year, sales of hemophilia A treatment in hospitals and clinics were tallied at 66 billion won.

 

While existing major drugs are sluggish in hospitals and clinics, JW Pharmaceutical's Hemlibra, which recently joined the market, has risen in sales for two consecutive years, rising to No.

 

2 in the market.

 

In the pharmaceutical industry, sales of Hemlibra are expected to increase further as benefits for Hemlibra are expected to increase in the first half.

 

As a result, there is a prospect that the hemophilia A treatment market, which has been led by GC Pharma, will be greatly shaken.

 

According to IQVIA, a pharmaceutical market research institute on the 7th, sales of hemophilia A treatment to hospitals and clinics last year were 66.2 billion won.

 

It decreased by 15% compared to 78.2 billion won in 2021.

 

Sales data generated by medical institutions operated by the Hemophilia Foundation were excluded from the tally.

 

In the pharmaceutical industry, if this data is included, it is estimated that the total sales volume would have been maintained at the level of the previous year.

 

While the overall market size of hospitals and clinics has been reduced, JW Pharmaceutical Hemlibra has succeeded in increasing sales for two consecutive years.

 

Last year, Hemlibra sales were 7.6 billion won, up 5% from 7.2 billion won in 2021.

 

Although the increase in sales last year was not large, it is analyzed that it rose to the second place in the market at once as major competing products performed poorly overall.

 

Hemlibra is a hemophilia A treatment introduced by JW Pharmaceutical in Korea.

 

In 2017, JW Pharmaceutical secured exclusive domestic development and sales rights for Hemlibra from Chugai Pharmaceuticals.

 

In January 2019, domestic item permission was obtained, and in May 2020, it was listed as a salary and released in earnest.

 

In the first year of its release, it recorded sales of 2.1 billion won.

 

It is evaluated that Hemlibra succeeded in making a soft landing in the market by improving the convenience of administration.

 

Hemlibra is the first subcutaneous injection formulation among hemophilia A treatments.

 

Existing treatments required patients to find a vein and inject themselves.

 

In particular, since many of the patients are children and adolescents, there was not a little inconvenience with the intravenous injection formulation.

 

Existing major products such as Takeda Pharmaceutical's Adynovate, Novo Nordisk's Novoseven, and GC Pharma's GreenMono saw a simultaneous decrease in sales.

 

Adynovate's sales last year were 19.5 billion won.

 

It decreased by 15% compared to 22.9 billion won in 2021.

 

Adynovate peaked at 27.7 billion won in 2019, and sales declined for three consecutive years until last year.

 

However, it still ranks first in the market.

 

In the case of Novoseven, it decreased by less than half from 14 billion won in 2021 to 5.5 billion won last year.

 

The market ranking fell from 2nd to 5th.

 

It recorded sales of 19.5 billion won in 2018, but since then, it has steadily decreased, and the new sales volume has reached a quarter of the level in four years.

 

Green Mono decreased from 8.3 billion won in 2021 to 6.6 billion won last year.

 

It's ranking in the hemophilia A treatment market fell from third to fourth.

 

The pharmaceutical industry predicts that Hemlibra will grow more rapidly in the future.

 

This is because the scope of benefits is expected to expand in the first half of this year.

 

Last February, the HIRA recognized the adequacy of Hemlibra's reimbursement as a 'prophylactic treatment for patients with severe non-antibody hemophilia A'.

 

JW Pharmaceutical plans to begin negotiating the drug price of Hemlibra with the NHIS soon.

 

It is expected that the benefit increase will be decided within the first half of this year at the earliest.

 

Currently, Hemlibra is covered only by antibody patients resistant to existing treatments.

 

It is known that 9 out of 10 hemophilia A patients in Korea do not have antibodies.

 

According to the 2019 Hemophilia White Paper, there are 1,746 patients with hemophilia A in Korea, of which 1,589 are non-antibody patients, accounting for 91%.

 

In effect, Hemlibra's salary range is expanded 10 times, and industry insiders predict that related sales will surge in the process.

 

Attention is focused on whether JW Pharmaceutical will emerge as a strong competitor to GC Pharma in the hemophilia A treatment market due to Hemlibra's coverage expansion.

 

GC Pharma dominates the domestic hemophilia A treatment market.

 

GC Pharma sells its own products, GreenMono and Greengene F.

 

In addition, Takeda Adynovate and Adynovate, the No.

 

1 and No.

 

3 products in the market, will be jointly sold.

 

The combined sales of the four products last year were 35.6 billion won, accounting for more than half of the hemophilia A treatment market last year.